ATHE · Alterity Therapeutics Ltd · Documents

Alterity Therapeutics said FDA minutes confirmed ATH434's Phase 3 design and registrational pathway for MSA; a new U.S. patent extends protection to 2045. Phase 3 preparations are underway, with cash of A$41.3 million at 30 September 2026.

Alterity Therapeutics Limited reports a proposed issue of securities identified as “ATH.”

Alterity Therapeutics Limited provided a Notice of Annual General Meeting/Proxy Form for its annual meeting.

Alterity Therapeutics approved changes to Dr David Stamler’s remuneration package effective 15 October 2026 and plans to seek shareholder approval at its upcoming annual general meeting for termination benefits included in the revised package.

Alterity Therapeutics announced that CEO David Stamler, M.D., will participate in a Fireside Chat at the Craig-Hallum Virtual Biotech Catalyst Conference on Thursday, October 22, 2026 at 2:30 p.m. ET.

Alterity Therapeutics said CEO David Stamler will present at the Canaccord Genuity Drug and Device Conference on Monday, October 12, 2026 at 3:50 p.m. AEST and host investor roundtable discussions.

Alterity Therapeutics reported that ATH434 50 mg slowed functional decline in Multiple System Atrophy by approximately 52% versus placebo at Week 52 on the 11-item UMSARS Part I (p=0.032), after adjusting for baseline CSF NfL.

Alterity Therapeutics Limited will hold its next Annual General Meeting at 11.00am (AEDT) on Friday 20 November 2026; director nominations must be received in writing by 5.00pm (AEST) on Friday 2 October 2026.